Therefore, in animal models of MASH, therapeutic suppression of CCR2 results in a reduction of liver injury and inflammatory responses, while also inhibiting the infiltration of CCR2+ monocytes 152. The gene discussed is CCR2; the disease is metabolic dysfunction-associated steatohepatitis.